Lipopolysaccharide Binding Protein is Associated with CVD Risk in Older Adults

Overview

Journal Aging Clin Exp Res

Publisher Springer

Specialty Geriatrics

Date 2020 Sep 8

PMID 32895891

Citations 11

Authors

Lisa M Roberts

Thomas W Buford

Affiliations

Soon will be listed here.

Abstract

Background: Intestinal (i.e., "gut") permeability may be related to cardiovascular disease (CVD) risk, but biomarkers for gut permeability are limited and associations with CVD risk are unknown-particularly among older adults.

Aims: This cross-sectional study aimed to determine if serum biomarkers related to gut permeability [intestinal fatty acid-binding protein (iFABP)] and bacterial toxin clearing [cluster of differentiation 14 (CD14), lipopolysaccharide binding protein (LBP)] are associated with CVD risk among older adults.

Methods: Older adults (n = 74, 69.6 ± 6.5-years-old) were stratified by CVD risk category. One-way ANOVAs determined differences in each biomarker by risk category, and associations with risk score were evaluated with Pearson correlations.

Results: LBP (p = 0.007), but not iFABP and CD14, was significantly different between CVD risk categories. Post-hoc tests indicated LBP was higher in moderate risk and high-moderate risk compared to the high risk category (p < 0.005). Evaluation of LBP and individual components in the risk score demonstrated a moderate, negative correlation of LBP with age and systolic blood pressure (r = - 0.335 and r = - 0.297) and a small positive correlation between LBP and total cholesterol and LDL cholesterol (r = 0.204 and r = 0.220).

Discussion/conclusion: Lower risk for CVD was associated with higher circulating concentrations of LBP, lower iFABP, and lower systemic inflammation in older adults. Further, there were small positive relationships between total and LDL cholesterol and circulating levels of LBP. These data suggest LBP may be a key component in reducing CVD risk in older adults.

Citing Articles

Increased plasma lipopolysaccharide-binding protein and altered inflammatory mediators reveal a pro-inflammatory state in overweight women.

Metz C, Brines M, Xue X, Chatterjee P, Adelson R, Roth J BMC Womens Health. 2025; 25(1):57.

PMID: 39930423 PMC: 11809003. DOI: 10.1186/s12905-025-03588-4.

Metabolic status is a key factor influencing proteomic changes in ewe granulosa cells induced by chronic BPS exposure.

Lebachelier de la Riviere M, Teteau O, Mahe C, Lasserre O, Desmarchais A, Uzbekova S BMC Genomics. 2024; 25(1):1095.

PMID: 39550580 PMC: 11568600. DOI: 10.1186/s12864-024-11034-2.

Beyond acute infection: molecular mechanisms underpinning cardiovascular complications in long COVID.

Mostafa R, Moustafa A Front Cardiovasc Med. 2024; 11:1268571.

PMID: 38495940 PMC: 10942004. DOI: 10.3389/fcvm.2024.1268571.

Proteomic Profiling of Dilated Cardiomyopathy Plasma Samples ─ Searching for Biomarkers with Potential to Predict the Outcome of Therapy.

Klimentova J, Rehulka P, Stulik J, Vozandychova V, Rehulkova H, Jurcova I J Proteome Res. 2024; 23(3):971-984.

PMID: 38363107 PMC: 10913098. DOI: 10.1021/acs.jproteome.3c00691.

Reduced Lipopolysaccharide-Binding Protein (LBP) Levels Are Associated with Non-Alcoholic Fatty Liver Disease (NAFLD) and Adipose Inflammation in Human Obesity.

Barchetta I, Cimini F, Sentinelli F, Chiappetta C, Di Cristofano C, Silecchia G Int J Mol Sci. 2023; 24(24).

PMID: 38139003 PMC: 10742626. DOI: 10.3390/ijms242417174.

References

Benjamin E, Muntner P, Alonso A, Bittencourt M, Callaway C, Carson A . Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation. 2019; 139(10):e56-e528. DOI: 10.1161/CIR.0000000000000659. View

Ferrucci L, Fabbri E . Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol. 2018; 15(9):505-522. PMC: 6146930. DOI: 10.1038/s41569-018-0064-2. View

Cevenini E, Caruso C, Candore G, Capri M, Nuzzo D, Duro G . Age-related inflammation: the contribution of different organs, tissues and systems. How to face it for therapeutic approaches. Curr Pharm Des. 2010; 16(6):609-18. DOI: 10.2174/138161210790883840. View

Franceschi C, Bonafe M, Valensin S, Olivieri F, De Luca M, Ottaviani E . Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000; 908:244-54. DOI: 10.1111/j.1749-6632.2000.tb06651.x. View

Ren W, Wu K, Li X, Luo M, Liu H, Zhang S . Age-related changes in small intestinal mucosa epithelium architecture and epithelial tight junction in rat models. Aging Clin Exp Res. 2013; 26(2):183-91. DOI: 10.1007/s40520-013-0148-0. View

Miao M, Xu Y, Sun M, Chang E, Cong X, Zhang J . BIS index monitoring and perioperative neurocognitive disorders in older adults: a systematic review and meta-analysis. Aging Clin Exp Res. 2019; 32(12):2449-2458. DOI: 10.1007/s40520-019-01433-x. View

Kim A, Ko H . Plasma concentrations of zonulin are elevated in obese men with fatty liver disease. Diabetes Metab Syndr Obes. 2018; 11:149-157. PMC: 5922244. DOI: 10.2147/DMSO.S163062. View

Li C, Gao M, Zhang W, Chen C, Zhou F, Hu Z . Zonulin Regulates Intestinal Permeability and Facilitates Enteric Bacteria Permeation in Coronary Artery Disease. Sci Rep. 2016; 6:29142. PMC: 4926221. DOI: 10.1038/srep29142. View

Ajamian M, Steer D, Rosella G, Gibson P . Serum zonulin as a marker of intestinal mucosal barrier function: May not be what it seems. PLoS One. 2019; 14(1):e0210728. PMC: 6331146. DOI: 10.1371/journal.pone.0210728. View

10.

Wells J, Brummer R, Derrien M, Macdonald T, Troost F, Cani P . Homeostasis of the gut barrier and potential biomarkers. Am J Physiol Gastrointest Liver Physiol. 2016; 312(3):G171-G193. PMC: 5440615. DOI: 10.1152/ajpgi.00048.2015. View

11.

Veerkamp J, Peeters R, Maatman R . Structural and functional features of different types of cytoplasmic fatty acid-binding proteins. Biochim Biophys Acta. 1991; 1081(1):1-24. DOI: 10.1016/0005-2760(91)90244-c. View

12.

Ockner R, Manning J . Fatty acid-binding protein in small intestine. Identification, isolation, and evidence for its role in cellular fatty acid transport. J Clin Invest. 1974; 54(2):326-38. PMC: 301560. DOI: 10.1172/JCI107768. View

13.

Vreugdenhil A, Wolters V, Adriaanse M, Van den Neucker A, van Bijnen A, Houwen R . Additional value of serum I-FABP levels for evaluating celiac disease activity in children. Scand J Gastroenterol. 2011; 46(12):1435-41. DOI: 10.3109/00365521.2011.627447. View

14.

Relja B, Szermutzky M, Henrich D, Maier M, de Haan J, Lubbers T . Intestinal-FABP and liver-FABP: Novel markers for severe abdominal injury. Acad Emerg Med. 2010; 17(7):729-35. DOI: 10.1111/j.1553-2712.2010.00792.x. View

15.

Kitai T, Kim Y, Kiefer K, Morales R, Borowski A, Grodin J . Circulating intestinal fatty acid-binding protein (I-FABP) levels in acute decompensated heart failure. Clin Biochem. 2017; 50(9):491-495. PMC: 5474350. DOI: 10.1016/j.clinbiochem.2017.02.014. View

16.

Adriaanse M, Tack G, Passos V, Damoiseaux J, Schreurs M, van Wijck K . Serum I-FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating autoantibodies. Aliment Pharmacol Ther. 2013; 37(4):482-90. DOI: 10.1111/apt.12194. View

17.

Kitchens R, Thompson P . Modulatory effects of sCD14 and LBP on LPS-host cell interactions. J Endotoxin Res. 2005; 11(4):225-9. DOI: 10.1179/096805105X46565. View

18.

Kitchens R, Wolfbauer G, Albers J, MUNFORD R . Plasma lipoproteins promote the release of bacterial lipopolysaccharide from the monocyte cell surface. J Biol Chem. 1999; 274(48):34116-22. DOI: 10.1074/jbc.274.48.34116. View

19.

Grundy S, Cleeman J, Merz C, Brewer Jr H, Clark L, Hunninghake D . Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110(2):227-39. DOI: 10.1161/01.CIR.0000133317.49796.0E. View

20.

DAgostino Sr R, Grundy S, Sullivan L, Wilson P . Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001; 286(2):180-7. DOI: 10.1001/jama.286.2.180. View